Detalles de la búsqueda
1.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 22(1): 43-69, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38394770
2.
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.
Biol Blood Marrow Transplant
; 18(8): 1150-63, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22510384
3.
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
Biol Blood Marrow Transplant
; 14(2): 246-55, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18215785
4.
Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy.
Blood Adv
; 4(19): 4798-4801, 2020 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33022063
5.
Successful treatment of both double minute of C-MYC and BCL-2 rearrangement containing large B-cell lymphoma with subsequent unfortunate development of therapy-related acute myeloid leukemia with t(3;3)(q26.2;q21).
Pathol Res Pract
; 211(11): 883-91, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26300063
6.
Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.
Haematologica
; 89(9): ECR30, 2004 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15377482
7.
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
Leuk Lymphoma
; 45(4): 695-8, 2004 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15160941
8.
t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia.
Hum Pathol
; 42(12): 2029-36, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21676437
9.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
Blood
; 111(1): 86-93, 2008 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17893227
10.
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
Blood
; 108(12): 3674-81, 2006 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16902153
Resultados
1 -
10
de 10
1
Próxima >
>>